Aurora Cannabis Inc. · TSX:ACB
Aurora Cannabis — Q1 2023 Earnings Presentation
6 slides from Aurora Cannabis's earnings presentation, Nov 10, 2022
Slide 1: Fiscal Q1 2023 Supplemental Information
FISCAL Q1 2023 SUPPLEMENTAL INFORMATION NOVEMBER 2022
Slide 2: Disclaimer
Disclaimer CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information contained in this presentation constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this presentation that are not statements of historical fact may be deemed
Slide 3: Key Takeaways
Key Takeaways Medical #1 Canadian LP in Global Medical Cannabis Revenues Leadership Positive Adj. Reiterates reaching Adjusted EBITDA profitability by December 31, 2022 EBITDA On track to achieve up to $170 million in annualized savings by December 31, 2022 Milestone Vastly Improved Approxim
Slide 4: FY23 Q1 Key Financial Highlights
FY23 Q1 Key Financial Highlights • Strong Canadian Medical Performance • #1 market share with strong and consistent margins • Direct-to-patient model bypasses provincial distributor • Technology investment drives high and repeatable margin and creates barrier to new entrants Canadian Wholesale Int’l
Slide 5: FY23 Q1 Key Financial Trends
FY23 Q1 Key Financial Trends Metric FY23 Q1 FY22 Q4 QoQ Improvement (%) Adjusted Gross Profit Before $24.4m $23.9m 2% Fair Value Adjustments (1) Adjusted Gross Margin Before Fair Value Adjustments on 50% 47% 3% Adjusted Net Revenue (1) SG&A and R&D excluding restructuring, non-recurring, $33.4m $37.
Slide 6: Investor Presentation
INVESTOR PRESENTATION Email: aurora@icrinc.com Website: investor.auroramj.com